Pulmonary arterial hypertension in France: Results from a national registry

American Journal of Respiratory and Critical Care Medicine

Volumn 173, Issue 9, 2006, Pages 1023-1030

  Humbert, Marc ^a   Sitbon, Olivier ^b   Chaouat, Ari ^b   Bertocchi, Michèle ^b   Habib, Gilbert ^b   Gressin, Virginie ^b   Yaici, Azzedine ^b   Weitzenblum, Emmanuel ^b   Cordier, Jean François ^b   Chabot, François ^b   Dromer, Claire ^b   Pison, Christophe ^b   Reynaud Gaubert, Martine ^b   Haloun, Alain ^b   Laurent, Marcel ^b   Hachulla, Eric ^b   Simonneau, Gérald ^b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b NONE

Author keywords

Cardiopulmonary hemodynamics; Prevalence; Pulmonary arterial hypertension registry; Six minute walk test

Indexed keywords

ANOREXIGENIC AGENT;

ADULT; AGED; ARTICLE; CONGENITAL HEART DISEASE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE REGISTRY; FAMILIAL DISEASE; FEMALE; FRANCE; HEART HEMODYNAMICS; HEART INDEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IDIOPATHIC DISEASE; INCIDENCE; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; PORTAL HYPERTENSION; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SURVIVAL RATE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; COHORT STUDIES; EXERCISE TOLERANCE; FEMALE; FRANCE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; INCIDENCE; MALE; MIDDLE AGED; PREVALENCE; REGISTRIES; SURVIVAL RATE;

EID: 33646269035     PISSN: 1073449X     EISSN: 1073449X     Source Type: Journal    
DOI: 10.1164/rccm.200510-1668OC     Document Type: Article

References (28)

1. Rubin LJ. Primary pulmonary hypertension. N Engl JMed 1997;336:111-117.
2. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003;361:1533-1544.
3. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004;351:1655-1665.
4. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43:5S-12S.
5. Galie N, Rubin LJ. New insights into a challenging disease: a review of the third world symposium on pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:1S.
6. Rich S, Danzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Koerner SK, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107:216-223.
7. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT, et al. Survival in patients with primary pulmonary hypertension. Ann Intern Med 1991;115:343-349.
8. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-1436.
9. Barst RJ,Mc Goon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, Gaine S. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:40S-47S.
10. Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, Herve P, Simonneau G. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998;12:265-270.
11. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F, Herve P, Simonneau G. Long-term response to calcium-channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-3111.
12. Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:35S-62S.
13. La Rosa E, Valensi P, Cohen R, Sou. K, Robache C, Cohen R, Le Clesiau H. Socioeconomic determinism of obesity in the Seine-Saint Denis area. Presse Med 2003;32:55-60.
14. Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 1998;158:1384-1387.
15. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, Nakanishi N, Miyatake K. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000;161:487-492.
16. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, Rainisio M, Simonneau G. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780-788.
17. Gurtner HP. Pulmonary hypertension, "plexogenic pulmonary arteriopathy" and the appetite depressant drug aminorex: post or propter? Bull Eur Physiopathol Respir 1979;15:897-923.
18. Simonneau G, Fartoukh M, Sitbon O, Humbert M, Jagot J-L, Herve P. Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Chest 1998;114:195S-199S.
19. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996;335:609-616.
20. Rich S, Rubin L, Walker AM, Schneeweiss S, Abenhaim L. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest 2000;117:870-874.
21. Koh WH, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996;35:989-993.
22. MacGregor AJ, Canavan R, Knight C, Denton CP, Davar J, Coghlan J, Black CM. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatol 2001;40:453-459.
23. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003;48:516-522.
24. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, Kahan A, Cabane J, Frances C, Launay D, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005;52:3792-3800.
25. Nunes H, Humbert M, Sitbon O, Morse JH, Deng Z, Knowles JA, Le Gall C, Parent F, Garcia G, Herve P, et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003;167:1433-1439.
26. Sitbon O, Gressin V, Speich R, Macdonald PS, Opravil M, Cooper DA, Fourme T, Humbert M, Delfraissy JF, Simonneau G. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;170:1212-1217.
27. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004;363:1461-1468.
28. Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB. Pulmonary-hepatic vascular disorders. Eur Respir J 2004;24:861-880.